Olimel N7 (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

Olimel N7 is used in parenteral nutrition to supply essential amino acids for patients who cannot obtain adequate nutrition via the gastrointestinal tract.

• Parenteral nutrition in patients unable to receive enteral feeding: Supplies a balanced mixture of essential amino acids to meet protein and nitrogen requirements.
• Critical illness or postoperative recovery: Supports protein synthesis and tissue repair during heightened metabolic demand.
• Management of malnutrition and amino acid deficiency: Helps restore nitrogen balance and prevent catabolism in severely malnourished individuals.

• Olimel N7 delivers a mixture of essential amino acids directly into the bloodstream, bypassing the digestive system. The supplied amino acids serve as substrates for ribosomal protein synthesis, replenish intracellular pools, and maintain nitrogen balance. By providing these building blocks, the solution facilitates tissue repair, immune function, and metabolic processes in patients receiving total parenteral nutrition. The formulation is isotonic and compatible with common intravenous fluids, allowing safe co‑administration with other nutrients and electrolytes.

Adverse reactions to Olimel N7 are generally related to the infusion of amino acids and may vary in frequency and severity.

Common Side Effects

• Hyperglycemia: Elevated blood glucose levels during or after infusion.
• Electrolyte disturbances: Shifts in potassium, sodium, or calcium concentrations.
• Infusion site reactions: Redness, pain, or swelling at the catheter site.
• Nausea or vomiting: Gastrointestinal discomfort following administration.

Serious or Rare Side Effects

• Anaphylactic reaction: Severe allergic response requiring immediate medical intervention.
• Metabolic alkalosis or acidosis: Significant disturbances in acid‑base balance.
• Hepatic dysfunction: Elevated liver enzymes indicating liver stress.

When using Olimel N7, clinicians should observe several safety measures to minimize risks and ensure optimal patient outcomes.

• Renal function assessment: Evaluate kidney performance before and during therapy.
• Hepatic monitoring: Check liver enzymes regularly to detect potential dysfunction.
• Electrolyte and glucose monitoring: Track serum electrolytes and blood glucose throughout infusion.
• Infusion rate adjustment: Modify administration speed in critically ill or hemodynamically unstable patients.
• Hypersensitivity screening: Avoid use in individuals with known allergy to any component of the solution.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Amino acid solutions can interact with other intravenous agents, affecting electrolyte balance or causing precipitation.

Major Interactions (Avoid)

• Concurrent potassium chloride infusion: May lead to dangerous hyperkalemia.
• Calcium‑containing solutions mixed together: Can precipitate calcium‑phosphate salts.
• Additional amino acid formulations: Excess nitrogen load may cause metabolic complications.

Moderate Interactions (Monitor Closely)

• Loop diuretics: Influence electrolyte excretion, requiring closer monitoring.
• Insulin therapy: May amplify glucose fluctuations during amino acid infusion.
• Nephrotoxic medications: Combined renal stress necessitates careful assessment.